Education
About Us
Working with TipRanks
Follow Us
Atai Beckley N.V. (DE:B72)
XETRA:B72
B72 Stock Chart & Stats
€3.16
-€0.07(-3.75%)
At close: 4:00 PM EST
€3.16
-€0.07(-3.75%)
Day’s Range― - ―
52-Week Range€1.06 - €6.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.14K
Market Cap
€1.07B
Enterprise Value€611.99M
Total Cash (Recent Filing)€256.04M
Total Debt (Recent Filing)€2.07M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Mar 26, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding364,745,970
10 Day Avg. Volume2,186
30 Day Avg. Volume1,140
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)4.62
Price to Sales (P/S)211.88
P/FCF Ratio-7.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.40Price Target Upside292.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€157.66K
Bulls Say, Bears Say
Bulls Say
Clinical Advancement & FDA Alignment (BPL-003)Constructive End-of-Phase 2 feedback and Breakthrough Therapy status materially reduce regulatory uncertainty for BPL-003. FDA alignment and a two-trial pivotal design create a clear development path, de-risking the lead asset and supporting long-term commercial planning and market entry timing.
Encouraging Mid-stage Efficacy Across PipelinePositive Phase 2a safety and efficacy signals for EMP-01, alongside published Phase 2 results for BPL-003, diversify program risk. Multiple mid-stage successes increase the probability at least one program reaches approval, support a multi-product commercial strategy, and strengthen the company’s therapeutic platform positioning.
Strengthened Liquidity And Multi-year RunwayA large cash balance and an explicit runway into 2029 provide breathing room to complete Phase 3 planning and initial execution without immediate financing. This liquidity supports sustained R&D investment and commercial readiness, reducing near-term financing pressure and enabling strategic execution of pivotal programs.
Bears Say
Consistent Heavy Cash BurnPersistent negative operating and free cash flow indicate the business consumes substantial capital to advance trials. Even with current cash, ongoing burn creates dependency on external funding over the medium term; this constrains optionality and may force financings or program prioritization if spend fails to moderate.
Large And Volatile Net Losses Vs Minimal RevenueVery large, volatile losses relative to tiny revenue underscore the company’s pre-revenue, R&D-heavy model. The scale of losses drives negative returns on equity and dilutes shareholder value over time if programs are delayed or fail to commercialize, limiting near-term chances for profitability.
Reliance On Equity Financing And Dilution RiskMaterial equity raises funded the improved cash position, signaling capital markets as the primary financing source. Continued reliance on dilutive issuances to support expensive Phase 3 and multi-program development risks long-term shareholder dilution and could pressure returns if programs do not deliver commensurate value.
Atai Beckley N.V. News
B72 FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was €1.06 and its highest was €6.00 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is €1.07B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is Mar 26, 2026 which is in 2 days.
How were Atai Beckley N.V.’s earnings last quarter?
Currently, no data Available
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. does not currently pay dividends.
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate is -0.09.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 364,745,970 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in DE:B72
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Company Description
Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
B72 Stock 12 Month Forecast
Average Price Target
€12.40
▲(292.45% Upside)
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Options Prices
Currently, No data available
---